PCI-34051 treatment also enhances the expression of natural killer group 2D (NKG2D) ligands that trigger the cytotoxic activity of NK cells and increases infiltration of CD69+ and NKG2D+ NK cells in glioma tumor mass [84]. The gene discussed is KLRK1; the disease is central nervous system cancer.